Crinetics Pharmaceuticals, Inc.
CRNXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCrinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and. The company carries a $9.01B market cap, placing it firmly in the mid-cap category. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.
Market Cap
$9.01B
Beta
0.09
P/E (TTM)
—
P/E (Fwd)
-21.00
EPS (TTM)
$-5.05
EPS (Fwd)
$-4.05
ROE
-42.4%
ROA
-26.3%
Cash
$1.21B
Total Debt
$47.2M
Free CF
-$248.8M
52W Change
155.1%
Annual Financials
Cash vs Debt
Where CRNX stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, CRNX finished 65.50% above its 150-day moving average ($51.33) and 67.72% above its 200-day moving average ($50.65). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRNX overbought or oversold?
At the September 2, 2026 close, CRNX's RSI(14) was 84.5, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.21B in cash comfortably exceeding the $47.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$248.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -42.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $4.7M to $7.7M.
The relatively low beta of 0.09 suggests CRNX is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Crinetics Pharmaceuticals, Inc.'s trajectory.